CN108484493A - 一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法 - Google Patents

一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法 Download PDF

Info

Publication number
CN108484493A
CN108484493A CN201810127491.4A CN201810127491A CN108484493A CN 108484493 A CN108484493 A CN 108484493A CN 201810127491 A CN201810127491 A CN 201810127491A CN 108484493 A CN108484493 A CN 108484493A
Authority
CN
China
Prior art keywords
dipyridyl derivatives
dinitro
conversion method
dipyridyl
difunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810127491.4A
Other languages
English (en)
Other versions
CN108484493B (zh
Inventor
蔡琥
谢永发
刘庆
岳树升
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanchang University
Original Assignee
Nanchang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanchang University filed Critical Nanchang University
Priority to CN201810127491.4A priority Critical patent/CN108484493B/zh
Publication of CN108484493A publication Critical patent/CN108484493A/zh
Application granted granted Critical
Publication of CN108484493B publication Critical patent/CN108484493B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals

Abstract

本发明涉及有机化学合成技术领域,具体涉及一种3,3’‑二硝基‑2,2’‑联吡啶衍生物的双官能团转化法,3,3’‑二硝基‑2,2’‑联吡啶衍生物与铜试剂在有机溶剂中,在空气条件下加热100~150℃反应10h,反应混合物再经过萃取、去除溶剂和柱层析分离后,得到纯品的3‑氨基‑3’‑羟基‑2,2’‑联吡啶衍生物。本发明通过3,3’‑二硝基‑2,2’‑联吡啶衍生物和铜试剂的作用下发生反应,可一步发生两个官能团转化得到3‑氨基‑3’‑羟基‑2,2’‑联吡啶衍生物,原料廉价易得,此合成方法简单,得到的产物比较单一,容易分离,并实现克级合成3‑氨基‑3’‑羟基‑2,2’‑联吡啶衍生物。

Description

一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法
技术领域
本发明属于有机化学合成技术领域,具体涉及一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法。
背景技术
3,3’-二羟基-2,2’-联吡啶由于分子内的质子转移常常表现出很强的荧光性质(Bulska, H.Chem.Phys.Lett.,1983,98,398.)。羟基2,2’-联吡啶衍生物也会表现出生物活性,如丝膜菌中分离得到的生物碱中含有羟基联吡啶的片段(Antikowiak,W.Z.;Gessner,W.P. Tetrahedron Lett.,1979,1931.)。联吡啶衍生物也常作为有机配体和金属铁,钴,镍,铜等形成配合物。鉴于羟基联吡啶衍生物可能具有生物活性、荧光性质及配位性质,即可应用于生物医药领域、材料领域或配位化学领域。
3,3’-二硝基-2,2’-联吡啶衍生物的两个硝基很容易被氯化亚锡等还原剂还原成氨基 ((1)Dou,C.;Long,X.;Wang,L.;et al.Angew.Chem.Int.Ed.2016,55,1436-1440.(2)Zhao, H.;Yue,Y.;Meng,W.;et al.Chinese J.Chem.2013,31,485-493),或者通过特定的条件将其转化成对称的化合物(反应式1)。通过检索文献发现目前报道的有关3,3’-二硝基-2,2’- 联吡啶衍生物的反应只能将两个硝基转过成相同的官能团(氨基,酰胺等),然而将两个硝基同时转化成不同的官能团的合成方法基本没有报道。鉴于前面所述3,3’-二羟基-2,2’- 联吡啶衍生物具有可能的荧光性质和生物活性,把3,3’-二羟基-2,2’-联吡啶衍生物的硝基同时转化成不同官能团的合成方法研究就显得非常的必要(反应式2)。
反应式1.3,3’-二硝基-2,2’-联吡啶的反应。
反应式2.官能团X≠官能团Y
本发明发现了一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法。
发明内容
本发明的目的在于提供一种3,3’-二硝基-2,2’-联吡啶衍生物转化成3-氨基-3-羟基 -2,2’-联吡啶衍生物的方法。
为实现上述目的,本发明采用的技术方案是:
本发明所述的3,3’-二硝基-2,2’-联吡啶衍生物双官能团转化法,以结构式如(Ⅰ)所示的3,3’-二硝基-2,2’-联吡啶衍生物与铜试剂在有机溶剂中,在空气条件下加热100~150℃反应10h,反应混合物再经过萃取、去除溶剂和柱层析分离后,得到纯品结构式如(Ⅱ)所示的3-氨基-3’-羟基-2,2’-联吡啶衍生物,反应式如下:
其中R为氢、C1~C40的脂肪基团、C4~C60内的芳香基团、烷氧基、羟基、硝基、胺基或者卤素。更进一步地,C1~C40的脂肪基团可为甲基、乙基、丙基、异丙基、丁基或苄基,C4~C60内的芳香基团可为吡啶衍生物基、苯基、取代苯基、1-萘基或2-萘基,卤素可为氟、氯、溴或碘。
进一步地,所述的铜试剂包括铜(Cu)、氯化铜水合物(CuCl2·2H2O)、醋酸铜水合物(Cu(OAc)2·H2O)或硝酸铜水合物(Cu(NO3)2·3H2O),铜试剂与3,3’-二硝基-2, 2’-联吡啶衍生物的摩尔比为1~5:1,优选为5:1。
进一步地,所述的有机溶剂可采用N,N-二甲基甲酰胺(DMF)、N,N-二甲基乙酰胺(DMA)、六甲基亚膦酰三胺(HMPT)、N-甲基吡咯烷酮(NMP)、二甲亚砜(DMSO) 或1,2-乙二醇。
本发明的3-氨基-3’-羟基-2,2’-联吡啶衍生物的合成通式为:
与现有技术相比,本发明的有益效果是:
1、本发明通过3,3’-二硝基-2,2’-联吡啶衍生物和铜试剂的作用下发生反应,一个硝基发生还原反应,另一个硝基发生取代反应,即一步发生两个官能团转化得到3-氨基-3’- 羟基-2,2’-联吡啶衍生物,此方法是首次发现。
2、此方法所用到的3,3’-二硝基-2,2’-联吡啶衍生物和铜试剂都是廉价易得的原料,此合成方法也很简单,得到的产物比较单一,容易分离。
3、此方法可以实现克级合成3-氨基-3’-羟基-2,2’-联吡啶衍生物。
具体实施方式
下面通过具体实施方式对本发明专利作进一步说明。
实施例1:3-氨基-3’-羟基-2,2’-联吡啶4a的制备。
在空气氛围中,3,3’-二硝基-2,2’-联吡啶(123mg,0.5mmol),二水合氯化铜(436mg,2.5mmol)加入到DMF(6.0mL)中,反应混合物加热到150℃持续10h。反应结束后冷却,加入蒸馏水90mL,乙二胺0.4mL后,用乙酸乙酯(30mL)萃取3次,合并有机相,用饱和食盐水(1.5mL)洗涤2次,有机相旋转蒸发除去溶剂,柱色谱分离,洗脱剂为乙酸乙酯/石油醚=1/40,回收原料15mg,转化率88%,得浅黄色固体41mg,产率50%。HR-MS实测值:[M+H]+,188.0812;计算值:[M+H]+,188.0818。
实施例2:3-氨基-3’-羟基-2,2’-联吡啶衍生物4b的制备。
在空气氛围中,3,3’-二硝基-2,2’-联吡啶(1.37g,5.0mmol),二水合氯化铜(3.41g,20mmol),蒸馏水(0.5mL)加入到DMF(12mL)中,反应混合物加热到130℃持续10h,反应结束后冷却,加入蒸馏水90mL,乙二胺0.4mL后,用乙酸乙酯(30mL) 萃取3次。合并有机相,用饱和食盐水(1.5mL)洗涤2次,有机相旋转蒸发除去溶剂,柱色谱分离,回收原料873mg,转化率36%,得浅黄色固体200mg,产率51%。HR-MS 实测值:[M+H]+,216.1134;计算值:[M+H]+,216.1131。
实施例3:3-氨基-3’-羟基-2,2’-联吡啶衍生物4c的制备。
在空气氛围中,3,3’-二硝基-2,2’-联吡啶(1.37g,5.0mmol),二水合氯化铜(3.41g,20mmol),蒸馏水(0.5mL)加入到DMF(12mL)中,反应混合物加热到130℃持续10h,反应结束后冷却,加入蒸馏水90mL,乙二胺0.4mL后,用乙酸乙酯(30mL) 萃取3次。合并有机相,用饱和食盐水(1.5mL)洗涤2次,有机相旋转蒸发除去溶剂,柱色谱分离,回收原料986mg,转化率28%,得浅黄色固体160mg,产率53%。HR-MS 实测值:[M+H]+,216.1137;计算值:[M+H]+,216.1131。
实施例3:3-氨基-3’-羟基-2,2’-联吡啶衍生物4d的制备。
在空气氛围中,3,3’-二硝基-2,2’-联吡啶(191mg,0.5mmol),二水合氯化铜(436mg,2.5mmol)加入到DMF(6mL)中,反应混合物加热到130℃持续10h,反应结束后冷却,加入蒸馏水90mL,乙二胺0.4mL后,用乙酸乙酯(30mL)萃取3次。合并有机相,用饱和食盐水(1.5mL)洗涤2次,有机相旋转蒸发除去溶剂,柱色谱分离,洗脱剂为乙酸乙酯/石油醚=1:60,回收原料155mg,转化率19%,得浅黄色固体16mg,产率 52%。HR-MS实测值:[M+H]+,324.0560;计算值:[M+H]+,324.0566。
尽管已经对本发明的技术方案做了较为详细的阐述和列举,应当理解,对于本领域技术人员来说,对上述实施例做出修改或者采用等同的替代方案,这对本领域的技术人员而言是显而易见,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。

Claims (7)

1.一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法,其特征在于,本发明所述的3,3’-二硝基-2,2’-联吡啶衍生物双官能团转化法,以结构式如(Ⅰ)所示的3,3’-二硝基-2,2’-联吡啶衍生物与铜试剂在有机溶剂中,在空气条件下加热100~150℃反应10h,反应混合物再经过萃取、去除溶剂和柱层析分离后,得到纯品结构式如(Ⅱ)所示的3-氨基-3’-羟基-2,2’-联吡啶衍生物,反应式如下:
2.根据权利要求1所述的一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法,其特征在于,其中R为氢、C1~C40的脂肪基团、C4~C60内的芳香基团、烷氧基、羟基、硝基、胺基或者卤素。
3.根据权利要求2所述的一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法,其特征在于,所述的C1~C40的脂肪基团为甲基、乙基、丙基、异丙基、丁基或苄基,所述的C4~C60内的芳香基团为吡啶衍生物基、苯基、取代苯基、1-萘基或2-萘基,所述的卤素为氟、氯、溴或碘。
4.根据权利要求1所述的一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法,其特征在于,所述的铜试剂为铜、氯化铜水合物、醋酸铜水合物或硝酸铜水合物中的一种。
5.根据权利要求1所述的一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法,其特征在于,所述的铜试剂与3,3’-二硝基-2,2’-联吡啶衍生物的摩尔比为1~5:1。
6.根据权利要求5所述的一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法,其特征在于,所述的铜试剂与3,3’-二硝基-2,2’-联吡啶衍生物的摩尔比为5:1。
7.根据权利要求1所述的一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法,其特征在于,所述的有机溶剂可采用N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、六甲基亚膦酰三胺、N-甲基吡咯烷酮、二甲亚砜或1,2-乙二醇中的一种。
CN201810127491.4A 2018-02-08 2018-02-08 一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法 Active CN108484493B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810127491.4A CN108484493B (zh) 2018-02-08 2018-02-08 一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810127491.4A CN108484493B (zh) 2018-02-08 2018-02-08 一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法

Publications (2)

Publication Number Publication Date
CN108484493A true CN108484493A (zh) 2018-09-04
CN108484493B CN108484493B (zh) 2021-11-19

Family

ID=63340091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810127491.4A Active CN108484493B (zh) 2018-02-08 2018-02-08 一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法

Country Status (1)

Country Link
CN (1) CN108484493B (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766088A (zh) * 2012-07-30 2012-11-07 无锡弗里斯特生物科技有限公司 一种合成4,4'-二溴-2,2'-联吡啶的新工艺
CN105646336A (zh) * 2015-01-07 2016-06-08 常州百敖威生物科技有限公司 一种4,4`-二甲氧基-2,2`-联吡啶的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766088A (zh) * 2012-07-30 2012-11-07 无锡弗里斯特生物科技有限公司 一种合成4,4'-二溴-2,2'-联吡啶的新工艺
CN105646336A (zh) * 2015-01-07 2016-06-08 常州百敖威生物科技有限公司 一种4,4`-二甲氧基-2,2`-联吡啶的制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRAIG R. RICE等: "The Coordination Chemistry of 3,3-Diamino-2,2-bipyridine and Its Dication: Exploring the Role of the Amino Groups by X-ray Crystallography", 《EUROPEAN JOURNAL OF INORGANIC CHEMISTRY》 *
KACZMAREK, LUKASZ: "Bipyridines. Part XVIII. On the synthesis of [2,2"-bipyridin]-3-ol and other novel 2,2"-bipyridine derivatives from [2,2"-bipyridine]-3,3"-diamine", 《BULLETIN OF THE POLISH ACADEMY OF SCIENCES, CHEMISTRY》 *
LUKASZ KACZMAREK: "Bipyridines. Part XVII. A convenient synthesis of some bipyridinediols and furodipyridines", 《POLISH JOURNAL OF CHEMISTRY》 *
卢俊瑞,等: "邻氨基二苯醚类重氮盐的水解及分子内缩合反应", 《高等学校化学学报》 *

Also Published As

Publication number Publication date
CN108484493B (zh) 2021-11-19

Similar Documents

Publication Publication Date Title
Roy et al. Trifluoromethylation of aryl and heteroaryl halides
Vasudevan et al. A post aza Baylis–Hillman/Heck coupling approach towards the synthesis of constrained scaffolds
CN113105402B (zh) 一种3,4,5-三取代的1,2,4-三氮唑化合物的制备方法
CN102146060B (zh) 制备吉非替尼及其中间体的方法
CN104844399B (zh) 一种合成2-氟代苯酚化合物的方法
Joy et al. A rapid and modified approach for C-7 amination and amidation of 4-methyl-7-nonafluorobutylsulfonyloxy coumarins under microwave irradiation
CN105198821B (zh) 洛昔替尼的制备方法
Ghosh et al. EDA complex directed N-centred radical generation from nitrosoarenes: a divergent synthetic approach
CN109293491B (zh) 一种芳基重氮盐脱重氮上酰基的方法
EP4229033A1 (en) Processes of preparing 3-fluoro-5-(((1s,2ar)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile
CN108484493A (zh) 一种3,3’-二硝基-2,2’-联吡啶衍生物的双官能团转化法
Le Phuong et al. Environmentally benign and diastereoselective synthesis of 2, 4, 5-trisubstituted-2-imidazolines
Diana et al. Nucleophilic substitutions in the isoindole series as a valuable tool to synthesize derivatives with antitumor activity
Kerdesky A novel and efficient method for the conversion of a trans-hexahydronaphthoxazine to a cis-isomer using boron tribromide
Mohammadi et al. New tetradentate Schiff bases of 2-amino-3, 5-dibromobenzaldehyde with aliphatic diamines and their metal complexes: Synthesis, characterization and thermal stability
Poola et al. A mild, catalyst-free synthesis of 2-aminopyridines
CN111533706B (zh) 一种1,4,6-三取代1,2-二氢-三嗪类化合物的制备方法
CN103965203B (zh) 一类咪唑[1,2-c]-喹唑啉-3(2H)-酮稠杂环化合物及其制备方法
Layek et al. A highly effective synthesis of 2-alkynyl-7-azaindoles: Pd/C-mediated alkynylation of heteroaryl halides in water
CN104803912B (zh) 一种医药中间体喹啉化合物的合成方法
CN105837579A (zh) 一种多取代苯并[4,5]咪唑并[1,2-b]吡唑衍生物的制备方法
CN107129464B (zh) 一种2,3,5,6-四取代对称吡啶的制备方法
Liu et al. Efficient synthesis of 1, 3, 5-trisubstituted benzenes via three Pd-mediated carbon–sulfur, carbon–nitrogen and carbon–carbon bond formation reactions
CN111269155A (zh) 一种无金属条件下烯基砜类化合物的合成方法
BR112014000473B1 (pt) processo para a preparação de 2-amino-5-ciano-n,3- dimetilbenzamida e compostos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant